Traffic Lights - Latest Updates

Last updated: 20/11/2019

Other updates on this site
Drug Name Classification Clinical Indication Comments
Alutard Bee venom ® (NEW) Black Preventative treatment for bee sting allergy

Not yet reviewed

Alutard Wasp venom ® (NEW) Black Preventative treatment for wasp sting allergy

Not yet reviewed

BROMOCRIPTINE (UPDATED) Amber Simple Hyperprolactinaemic disorders

Annual monitoring undertaken in secondary care Primary care should be aware of fibrotic reactions

BUDESONIDE M/R TABLETS (Cortiment®) (NEW) Amber Simple Ulcerative colitis

See formulary for place in therapy

CANNABIDIOL(Epidyolex®) (NEW) Black For use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam

Not yet reviewed

CELECOXIB (NEW) Amber Simple Inflammatory pain associated with cancer or other palliative conditions
CELECOXIB (UPDATED) Black Pain not associated with cancer or palliative care
DABIGATRAN (UPDATED) Amber Simple Venous thromboembolism (treatment and long term secondary prevention)

In line with NICE TA 327


DABIGATRAN Red Prevention of Venous Thromboembolism (VTE) following knee / hip replacement surgery

In line with NICE  TA 157

DAPAGLIFLOZIN (NEW) Amber Simple With insulin for treating Type 1 diabetes

In line with NICE TA597

Implementation date 28th November 2019


Use in line with NICE TA354



GANIRELIX ACETATE (Fyremadel®) (NEW) Red Prevention of premature luteinising hormone (LH) surges in women undergoing ovarian stimulation for IVF
LETERMOVIR (Prevymis®) (NEW) Red Prevention of cytomegalovirus disease after a stem cell transplant

In line with NICE TA591

Implementation date 31st October 2019

LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (Levosert®) (UPDATED) Green Contraception or heavy menstrual bleeding
LUBIPROSTONE (UPDATED) Green Chronic refractory constipation

Discontinued in the UK for commercial reasons

MELATONIN (Colonis®) (NEW) Black Jet lag
NALDEMEDINE TOSYLATE(Rizmoic®) (NEW) Black opioid-induced constipation

Not yet reviewed

PARATHYROID HORMONE (Natpar®) (UPDATED) Red Post-trial continuation of treatment of chronic hypoparathyroidism when standard therapy alone is inadequate.
PARECOXIB(Dynastat ®) (NEW) Amber Full SCA Inflammatory pain associated with cancer or other palliative conditions
PRASTERONE 6.5mg PESSARY (Intrarosa®) (NEW) Black Vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms

Not yet reviewed.

PRUCALOPRIDE (UPDATED) Green Chronic refractory constipation
RAVULIZUMAB (Ultomiris®) (NEW) Black Paroxysmal nocturnal haemoglobinuria

Not yet reviewed

RISANKIZUMAB (Skyrizi®) (UPDATED) Red Moderate to severe plaque psoriasis

In line with NICE TA596

RIVASTIGMINE (UPDATED) Amber Simple Alzheimer's disease

in line with NICE NG 97

Change in traffic light status from 1st October 2018

SIROLIMUS GEL (NEW) Red Angiofibromas associated with tuberous sclerosis complex

In line with NICE TA599.

Implementation date 4th December 2019.

TESTOSTERONE GEL (Tostran ®) (UPDATED) Amber Simple Testosterone deficiency in menopausal women (unlicensed)

Tostran brand only. As per NICE NG 23

TEZACAFTOR AND IVACAFTOR (Symkevi ®) (NEW) Red Cystic Fibrosis
TOFACITINIB (NEW) Red Moderately to severely active ulcerative colitis

In line with NICE TA 547

Implementation date 28th February 2019

ULIPRISTAL ACETATE (Esmya ®) (UPDATED) Red Uterine fibroids

In line with MHRA alert August 2018 regarding risks of liver injury.

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more